Previous 10 | Next 10 |
Journal Article Evaluates Viability of Neuroprotectants as a functional Endpoint in Ischemic Stroke and Other Diseases BOSTON, MASSACHUSETTS, Dec. 05, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs ...
Phoenix, Arizona--(Newsfile Corp. - December 3, 2019) - The Stock Day Podcast welcomed Bioxytran, Inc. (OTCQB: BIXT) ("the Company"), a developmental stage biotechnology company. CEO of the Company, Dr. David Platt, joined Stock Day host Everett Jolly. To begin the interview, Platt shared som...
MDX Viewer provides essential data in critical care patients BOSTON, MASSACHUSETTS, Oct. 28, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company focused on a pipeline of drugs designed to treat hypoxia, by delivering nanoscale oxygen carrie...
Phoenix, Arizona--(Newsfile Corp. - October 21, 2019) - The Stock Day Podcast welcomed Bioxytran, Inc. (OTCQB: BIXT) ("the Company"), a developmental stage biotechnology company. CEO of the Company, David Platt, joined Stock Day host Everett Jolly. Jolly began the interview by welcoming Plat...
Platform technology destined to measure and treat hypoxia BOSTON, MASSACHUSETTS, Oct. 16, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), is a developmental stage biotechnology company, focused on a pipeline of drugs designed to treat hypoxia, by delivering nanoscale oxygen c...
BOSTON, MASSACHUSETTS, Sept. 13, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company, focused on delivering a small molecule carrying oxygen to the brains of stroke victims, announced today that it has invited John Jensen and Dr. Patrick Huddie ...
BOSTON, MASSACHUSETTS, Aug. 30, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company developing a pipeline of novel anti-necrosis drugs designed to treat stroke victims announced today they will be attending both the RHK Capital 2019 Disruptive G...
BOSTON, MASSACHUSETTS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company developing a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced to...
BOSTON, MASSACHUSETTS, Aug. 01, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims, announced today t...
BOSTON, July 26, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company developing a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that it has...
News, Short Squeeze, Breakout and More Instantly...
COPT Defense Properties of Beneficial Interest (CDP) is expected to report $0.64 for Q2 2024 Bank of Marin Bancorp (BMRC) is expected to report $0.19 for Q2 2024 Oak Ridge Financial Services Inc (BKOR) is expected to report for Q2 2024 D/B/A Centerspace (CSR) is expected to report $1....
The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to t...
BXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced that Bioxtran’s...